Captrust Financial Advisors Sells 9,663 Shares of Progyny, Inc. (NASDAQ:PGNY)

Captrust Financial Advisors decreased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 4.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 221,082 shares of the company’s stock after selling 9,663 shares during the period. Captrust Financial Advisors owned about 0.24% of Progyny worth $3,705,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Public Sector Pension Investment Board bought a new position in shares of Progyny during the third quarter worth approximately $2,792,000. Quantbot Technologies LP bought a new position in shares of Progyny during the third quarter worth approximately $2,187,000. Crestwood Capital Management L.P. increased its stake in shares of Progyny by 17.9% during the third quarter. Crestwood Capital Management L.P. now owns 436,081 shares of the company’s stock worth $7,309,000 after purchasing an additional 66,331 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Progyny during the third quarter worth approximately $1,613,000. Finally, Algert Global LLC increased its stake in shares of Progyny by 138.7% during the third quarter. Algert Global LLC now owns 184,885 shares of the company’s stock worth $3,099,000 after purchasing an additional 107,432 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

Shares of PGNY stock opened at $14.85 on Wednesday. The stock’s fifty day moving average price is $15.79 and its two-hundred day moving average price is $22.07. The company has a market cap of $1.26 billion, a PE ratio of 25.60, a P/E/G ratio of 1.80 and a beta of 1.35. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNY) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. During the same period in the prior year, the business posted $0.16 EPS. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. On average, equities analysts predict that Progyny, Inc. will post 0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PGNY. Barclays lowered their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. BTIG Research lowered Progyny from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $17.00 price objective (down previously from $22.00) on shares of Progyny in a research note on Monday. Bank of America lowered their price objective on Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Canaccord Genuity Group lowered their price objective on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.